158 related articles for article (PubMed ID: 24598183)
41. Management of chronic graft-versus-host disease.
Baker M; McKiernan P
Clin J Oncol Nurs; 2011 Aug; 15(4):429-32. PubMed ID: 21810577
[TBL] [Abstract][Full Text] [Related]
42. Update on the management of acute graft-versus-host disease.
Bolaños-Meade J
Curr Opin Oncol; 2006 Mar; 18(2):120-5. PubMed ID: 16462179
[TBL] [Abstract][Full Text] [Related]
43. Nonpharmacologic treatment of chronic graft-versus-host disease in children and adolescents.
Lawitschka A; Ball L; Peters C
Biol Blood Marrow Transplant; 2012 Jan; 18(1 Suppl):S74-81. PubMed ID: 22226116
[TBL] [Abstract][Full Text] [Related]
44. Sirolimus-containing graft-versus-host disease prophylaxis in patients with lymphoma.
Mehta J
J Clin Oncol; 2009 Oct; 27(28):e138; author reply e139-40. PubMed ID: 19720890
[No Abstract] [Full Text] [Related]
45. [Clinical manifestation and related-risk factors analysis of chronic graft-versus-host disease].
Weng JY; Du X; Lu ZS
Zhonghua Xue Ye Xue Za Zhi; 2013 Feb; 34(2):168-70. PubMed ID: 23611230
[No Abstract] [Full Text] [Related]
46. Chronic graft versus host disease of oral mucosa: review of available therapies.
Imanguli MM; Pavletic SZ; Guadagnini JP; Brahim JS; Atkinson JC
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2006 Feb; 101(2):175-83. PubMed ID: 16448918
[TBL] [Abstract][Full Text] [Related]
47. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
48. Target blood concentrations of CYA and tacrolimus in randomized controlled trials for the prevention of acute GVHD after hematopoietic SCT.
Oshima K; Sato M; Terasako K; Kimura S; Okuda S; Kako S; Kanda Y
Bone Marrow Transplant; 2010 Apr; 45(4):781-2. PubMed ID: 19701249
[No Abstract] [Full Text] [Related]
49. Graft-versus-host disease: a complex long-term side effect of hematopoietic stem cell transplant.
Barton-Burke M; Dwinell DM; Kafkas L; Lavalley C; Sands H; Proctor C; Johnson E
Oncology (Williston Park); 2008 Oct; 22(11 Suppl Nurse Ed):31-45. PubMed ID: 19856578
[TBL] [Abstract][Full Text] [Related]
50. [Mesenchymal stem cells as salvage therapy for steroid resistant acute graft-versus-host disease following haploidentical hematopoietic stem cell transplantation].
Xue M; Wang ZD; Dong L
Zhonghua Xue Ye Xue Za Zhi; 2011 Dec; 32(12):878-80. PubMed ID: 22339970
[No Abstract] [Full Text] [Related]
51. Exercise benefits in chronic graft versus host disease: a murine model study.
Fiuza-Luces C; Soares-Miranda L; González-Murillo A; Palacio JM; Colmenero I; Casco F; Melén GJ; Delmiro A; Morán M; Ramírez M; Lucia A
Med Sci Sports Exerc; 2013 Sep; 45(9):1703-11. PubMed ID: 23954992
[TBL] [Abstract][Full Text] [Related]
52. [Diagnosis and management of chronic graft-versus-host disease].
Inamoto Y
Rinsho Ketsueki; 2014 Oct; 55(10):2113-24. PubMed ID: 25297778
[No Abstract] [Full Text] [Related]
53. Guest editorial: Role of monoclonal antibodies for the prevention and treatment of graft-versus-host disease.
Kanda Y
Int J Hematol; 2011 May; 93(5):569-570. PubMed ID: 21557042
[No Abstract] [Full Text] [Related]
54. The management and outcome of chronic graft-versus-host disease.
Fraser CJ; Scott Baker K
Br J Haematol; 2007 Jul; 138(2):131-45. PubMed ID: 17593020
[TBL] [Abstract][Full Text] [Related]
55. Graft-versus-host disease is associated with a lower relapse incidence after hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia.
Nordlander A; Mattsson J; Ringdén O; Leblanc K; Gustafsson B; Ljungman P; Svenberg P; Svennilson J; Remberger M
Biol Blood Marrow Transplant; 2004 Mar; 10(3):195-203. PubMed ID: 14993885
[TBL] [Abstract][Full Text] [Related]
56. Sirolimus immunosuppression for graft-versus-host disease prophylaxis and therapy: an update.
Cutler C; Antin JH
Curr Opin Hematol; 2010 Nov; 17(6):500-4. PubMed ID: 20717025
[TBL] [Abstract][Full Text] [Related]
57. Progress and prospects: graft-versus-host disease.
Mastaglio S; Stanghellini MT; Bordignon C; Bondanza A; Ciceri F; Bonini C
Gene Ther; 2010 Nov; 17(11):1309-17. PubMed ID: 20508597
[TBL] [Abstract][Full Text] [Related]
58. [Graft-versus-host disease: friend or foe?].
Kanda Y
Rinsho Ketsueki; 2008 Aug; 49(8):583-91. PubMed ID: 18800606
[No Abstract] [Full Text] [Related]
59. Novel strategies for the treatment and diagnosis of graft-versus-host-disease.
Ferrara JL
Best Pract Res Clin Haematol; 2007 Mar; 20(1):91-7. PubMed ID: 17336259
[TBL] [Abstract][Full Text] [Related]
60. Graft-versus-host disease of the skin and adjacent mucous membranes.
Ziemer M
J Dtsch Dermatol Ges; 2013 Jun; 11(6):477-95. PubMed ID: 23721594
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
